Natco Pharma Ltd - Company Profile
Powered by 
All the data and insights you need on Natco Pharma Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Natco Pharma Ltd Strategy Report
- Understand Natco Pharma Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Natco Pharma Ltd (Natco Pharma) focuses on the discovery, development, manufacturing, and commercialization of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated for the treatment of multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn's disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage formulation facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Natco House, Road No 2, Banjara Hills, Hyderabad, Telangana, 500034
Website
www.natcopharma.co.in
Telephone
91 40 23547532
No of Employees
3,979
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NATCOPHARM (NSE)
Revenue (2022)
$345.0M
39.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
320.8%
(2022 vs 2021)
Market Cap*
$2.1B
Net Profit Margin (2022)
XYZ
202.3%
(2022 vs 2021)
* As of and is in US$
Natco Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Finished Dosage Formulations: | Contract Manufacturing | Baricitinib |
| Oncology – Hematology | Tenofovir Alafenamide Fumarate | |
| Oncology – Solid Tumors | NATGEN | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Financing Agreements | In January, the company invested US$2 million in Cellogen Therapeutics Private Limited. |
| 2023 | Acquisitions/Mergers/Takeovers | In August, the company acquired a 5.79% stake in ISCA Inc. |
| 2023 | Regulatory Approval | In June, the company received final approval for its abbreviated new drug application for Tipiracil Hydrochloride and Trifluridine Tablets (generic for Lonsurf) from the US Food and Drug Administration (USFDA). |
Competitor Comparison
| Key Parameters | Natco Pharma Ltd | Biocon Ltd | Piramal Enterprises Ltd | Divi's Laboratories Ltd | Jubilant Pharmova Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Bangalore | Mumbai | Hyderabad | Noida |
| State/Province | Telangana | Karnataka | Maharashtra | Telangana | Uttar Pradesh |
| No. of Employees | 3,979 | 3,408 | 12,220 | 16,950 | 1,034 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| G.S. Murthy | Chairman | Executive Board | 2022 | - |
| Rajeev Nannapaneni | Chief Executive Officer; Director | Executive Board | 2022 | 46 |
| S.V.V.N Appa Rao | Chief Financial Officer | Senior Management | - | - |
| Venkaiah Chowdary Nannapaneni | Director; Managing Director | Executive Board | - | 78 |
| Linga Rao Donthineni | Director; President - Technical Affairs | Executive Board | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward